Identification of Immune-Related Seven-Long Non-Coding RNA Signature for Overall Survival and Validation of the Effect of LINC01270 in Malignant Phenotypes of Clear Cell Renal Carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524. doi:10.3322/caac.21411
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–366. doi:10.1056/NEJMra1601333
   PubMed Web of Science ®Google Scholar
• Bex A, Albiges L, Ljungberg B, et al. Updated European Association of Urology guidelines regarding adjuvant therapy for renal cell carcinoma. Eur Urol. 2017;71(5):719–722. doi:10.1016/j.eururo.2016.11.034
   PubMed Web of Science ®Google Scholar
• Sánchez-Gastaldo A, Kempf E, González Del Alba A, Duran I. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat Rev. 2017;60:77–89. doi:10.1016/j.ctrv.2017.08.010
   PubMed Web of Science ®Google Scholar
• Parker WP, Cheville JC, Frank I, et al. Application of the Stage, Size, Grade, and Necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients. Eur Urol. 2017;71(4):665–673. doi:10.1016/j.eururo.2016.05.034
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–1657. doi:10.1200/JCO.2001.19.6.1649
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment f or advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, Phase 3 trial. Lancet Oncol. 2022;23(7):888–898. doi:10.1016/S1470-2045(22)00290-X
   PubMed Web of Science ®Google Scholar
• Ciccarese C, Brunelli M, Montironi R, et al. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016;49:37–44. doi:10.1016/j.ctrv.2016.07.003
   PubMed Web of Science ®Google Scholar
• Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267–279. doi:10.1016/j.eururo.2015.02.032
   PubMed Web of Science ®Google Scholar
• Najafi S, Khatami SH, Khorsand M, et al. Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis. Exp Cell Res. 2022;418(2):113294. doi:10.1016/j.yexcr.2022.113294
   PubMed Web of Science ®Google Scholar
• Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 2016;14(1):42–54. doi:10.1016/j.gpb.2015.09.006
   PubMed Web of Science ®Google Scholar
• Nallasamy P, Chava S, Verma SS, et al. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: immuno-oncology perspective. Paper presented at: Seminars in cancer biology; 2018.
   Google Scholar
• Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.004
   PubMed Web of Science ®Google Scholar
• von Roemeling CA, Radisky DC, Marlow LA, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014;74(17):4796–4810. doi:10.1158/0008-5472.CAN-14-0210
   PubMed Web of Science ®Google Scholar
• Wotschofsky Z, Gummlich L, Liep J, et al. Integrated microRNA and mRNA signature associated with the transition from the locally confined to the metastasized clear cell renal cell carcinoma exemplified by miR-146-5p. PLoS One. 2016;11(2):e0148746–e0148746. doi:10.1371/journal.pone.0148746
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Wang W, Song J, Zhang W, et al. Identification of long non-coding RNA signatures for specific disease-free prognosis in clear cell renal carcinoma. IEEE Access. 2019;7:99290–99298. doi:10.1109/ACCESS.2019.2929588
   Web of Science ®Google Scholar
• Song J, Liu T, Zhao Z, et al. Genetic polymorphisms of long non-coding RNA RP11-37B2.1 associate with susceptibility of tuberculosis and adverse events of antituberculosis drugs in west China. J Clin Lab Anal. 2019;33:e22880. doi:10.1002/jcla.22880
   Web of Science ®Google Scholar
• Hacisuleyman E, Goff LA, Trapnell C, et al. Topological organization of multichromosomal regions by the long intergenic non-coding RNA Firre. Nat Struct Mol Biol. 2014;21(2):198–206. doi:10.1038/nsmb.2764
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Hirano T. Gathering around Firre. Nat Struct Mol Biol. 2014;21:207. doi:10.1038/nsmb.2782
   Web of Science ®Google Scholar
• Yang F, Deng X, Ma W, et al. The lncRNA Firre anchors the inactive X chromosome to the nucleolus by binding CTCF and maintains H3K27me3 methylation. Genome Biol. 2015;16(1):52. doi:10.1186/s13059-015-0618-0
   PubMedGoogle Scholar
• Lu Y, Liu X, Xie M, et al. The NF-κB-responsive long noncoding RNA FIRRE regulates posttranscriptional regulation of inflammatory gene expression through interacting with hnRNPU. J Immunol. 2017;199(10):3571–3582. doi:10.4049/jimmunol.1700091
   PubMed Web of Science ®Google Scholar